Navigation Links
Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Date:7/22/2009

'Hebron Institute of Oncology in Barcelona and the principal investigator of this study. "One goal of this study was to evaluate the success of an all-oral regimen, which may represent a unique treatment option for patients with breast cancer."

Breast Cancer Trial Design

The randomized, double-blind, placebo-controlled Phase 2 study evaluated Nexavar in combination with the oral chemotherapeutic agent, capecitabine, in 229 patients. These patients had locally advanced or metastatic HER-2 negative breast cancer and had received no more than one prior chemotherapy in this setting. The primary endpoint of the study was progression-free survival. There were several secondary endpoints, including overall survival, time to progression, and safety. Patients were randomized to receive 400 mg of oral Nexavar or matching placebo twice daily, in addition to 1000 mg/m(2) of capecitabine twice daily for 14 days followed by a seven day rest from capecitabine.

About the Nexavar Clinical Program in Breast Cancer

Nexavar is being evaluated in collaboration with investigators and cooperative groups in a variety of treatment settings for patients with breast cancer. Among these trials are three ongoing randomized Phase 2 studies, including a trial to evaluate Nexavar plus paclitaxel in the first-line setting, a trial to evaluate Nexavar plus gemcitabine or capecitabine in the first- or second-line setting following progression on bevacizumab, and a trial to evaluate Nexavar plus docetaxel and/or letrozole in the first-line setting.

About Breast Cancer

Breast cancer was the most commonly diagnosed cancer among women worldwide in 2007-2008 (approximately 1.3 million cases), and the leading cause of death among women with cancer (approximately 465,000 deaths). It is the most commonly diagnosed cancer among women in the United States (1 in 4 cancer diagnoses is breast ca
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
2. New Analyses Confirm Nexavars Efficacy and Safety in Multiple Patient Subsets With Liver Cancer
3. Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer
4. Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
5. Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
6. Promising drug combination may help those with ocular melanoma that has spread
7. Combination therapy reverses effects of portal hypertension in rats
8. Combination vaccines okay for infants, study shows
9. Antidepressants and painkillers - a dangerous combination
10. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
11. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... San Jose, California (PRWEB) September 22, 2014 ... densitometry is a diagnostic procedure that provides quantitative measurement ... for bone densitometers is driven by the rapidly aging ... osteoporosis and fractures. The elderly represent potential candidates for ... to structural deterioration of bone tissue as a result ...
(Date:9/22/2014)... found a way to find the proverbial needle in ... in The Journal of Experimental Medicine ... random mistakes (mutations). This process creates new versions of ... by immune cells called T cells, prompting the cells ... current ability to identify all of the mutations in ...
(Date:9/22/2014)... Researchers have found that environment has a much ... a severe, often painful food allergy that renders ... foods. , Eosinophils are normal cellular components ... too many eosinophils they can cause a variety ... inflammation and resulting tissue damage, often in the ...
(Date:9/22/2014)... an old acquaintance: a certain module of the familiar ... anchor protein. The researchers report their findings in ... into peroxisome , Peroxisomes are of vital importance ... cellular toxins. In order for them to fulfil this ... the peroxisomes first. The bulk is brought into a ...
(Date:9/22/2014)... Cancer Science Institute of Singapore (CSI Singapore) at ... an increase in a gene known as Leo1 ... acute myelogenous leukaemia (AML), increasing the incidence of ... Wee Joo, Deputy Director and Senior Principal Investigator ... University Cancer Institute, Singapore, the scientists discovered that ...
Breaking Medicine News(10 mins):Health News:Rising Incidence of Osteoporosis Spurs Growth in the Global Bone Densitometers Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Rising Incidence of Osteoporosis Spurs Growth in the Global Bone Densitometers Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Environment plays bigger role than genetics in food allergic disease eosinophilic esophagitis 2Health News:The accelerator of molecular motors 2Health News:Singapore researchers discover a gene that increases incidence of AML 2
... N.C. Some invasive procedures that are becoming increasingly common ... narrowed arteries in and around the kidneys may not be ... Forest University Baptist Medical Center. The study shows ... to a dangerous blockage in a very small percentage of ...
... is a statement from Mark Ganz, president and chief executive ... vote today on the America,s Healthy Future Act : ... economically sustainable health care reform package will be adopted this ... long-term health care security and stability for all Americans. ...
... , AARP/Blue Zones Vitality Project Inspired Residents to Make ... Minn., Oct. 13 The AARP(R)/Blue Zones(R) Vitality ... that the life expectancy of the citizens of Albert ... during the unprecedented 10-month city-wide health makeover. The ...
... Health Insurance Plans (AHIP) President and CEO Karen Ignagni ... care reform legislation in the Senate Finance Committee: , ... covers all Americans, improves quality, and puts the health ... plans have proposed guaranteed coverage, elimination of pre-existing condition ...
... , - Thomas Curran, Ph.D., FRS, is expert ... 13 A prominent scientist at ... been elected to the Institute of Medicine. Dr. Curran has ... Institute of Medicine (IOM) yesterday announced the election of 65 ...
... Speaker Nancy Pelosi issued the following statement ... committee,s health insurance reform proposal. , "The Senate Finance ... a health insurance reform bill to President Obama,s desk that ... and doctors, improve quality, and make health care affordable for ...
Cached Medicine News:Health News:Study questions need for routine intervention in patients with renovascular disease 2Health News:Study questions need for routine intervention in patients with renovascular disease 3Health News:Albert Lea Residents Add 3.1 Years of Life Expectancy 2Health News:Albert Lea Residents Add 3.1 Years of Life Expectancy 3Health News:Albert Lea Residents Add 3.1 Years of Life Expectancy 4Health News:Albert Lea Residents Add 3.1 Years of Life Expectancy 5Health News:AHIP Statement on Passage of Senate Finance Committee Legislation 2Health News:Children's Hospital Oncology Researcher Elected to Institute of Medicine 2Health News:Children's Hospital Oncology Researcher Elected to Institute of Medicine 3
(Date:9/22/2014)... DALLAS and NEW YORK ... PHARMACEUTICALS, INC. (OTCBB: ACCP), has signed an exclusive, ... for the development and commercialization of its proprietary ... new corporate management team and its intention to ... Biopharmaceuticals, Inc.™, and its plans to pursue a ...
(Date:9/22/2014)... Sept. 22, 2014 Research and Markets ... Chinese Diclofenac Industry Report 2014" report to their ... Industry Report 2014 is a professional and in-depth study ... with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:9/20/2014)... 20, 2014 /CNW/ - The issue: Mylan Pharmaceuticals ULC Canada, ... of its Mylan-Nitro Spray 0.4 mg/metered dose due to the ... pump component. A missing "dip tube" could ... the patient. This defect may lead patients to believe they ... to access it. Not receiving nitroglycerin could place them at ...
Breaking Medicine Technology:Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6Global and Chinese Diclofenac Industry Report 2014 2Advisory - Mylan Pharmaceuticals recalling nitroglycerin spray due to defective pump 2
... is a family of solutions that ... individuals inside hospitals, healthcare facilities, or ... The target tracking areas are networked ... of radio frequency identification (RFID) readers ...
Assetrac allows identification, location, and protection of your assets....
... The RoamAlert Integrity system builds ... ECO. All door controllers in the ... computer running a standard Windows® operating ... the use of a personal computer, ...
... uses RFID to gather patient ... departments such as surgical and ... updates of patient location to ... care events have occurred and ...
Medicine Products: